Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B

Authors :: Lau, George K.K.
Marcellin, Patrick
Piratvisuth, Teerha
Thongsawat, Satawat
Kang Xian Luo
Cooksley, Graham
Gane, Edward
Fried, Michael W.
Wan Cheng Chow
Seung Woon Paik
Wen Yu Chang
Berg, Thomas
Flisiak, Robert
McLoud, Philip
Pluck, Nigel
Source :: The New England Journal of Medicine. June 30, 2005, Vol. 352 Issue 26, p2682, 14 p.
Publication Year :: 2005
Abstract: The efficacy and safety of pegylated interferon alpha plus lamivudine, pegylated alfa without lamivudine, and lamivudine alone for the treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B are compared. It is concluded that in patients with HBeAg-positive chronic hepatitis B, peginterferon alfa-2a offers superior efficacy over lamivudine, on the basis of HBeAg seroconversion, HBV DNA suppression and HBsAg seroconversion.

Subjects :: Peginterferon (Medication) -- Dosage and administration
Hepatitis B -- Drug therapy
Lamivudine -- Dosage and administration

Tools